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Abstract
Background: Optimal dosing of oral tyrosine kinase inhibitor therapy is critical to treatment success and survival of patients
with chronic myeloid leukemia (CML). Drug intolerance secondary to toxicities and nonadherence are significant factors in
treatment failure.
Objective: The objective of this study was to develop and pilot-test the clinical feasibility and acceptability of a mobile health
system (REMIND) to increase oral drug adherence and patient symptom self-management among people with CML (chronic
phase).
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Methods: A multifaceted intervention was iteratively developed using the intervention development framework by Schofield
and Chambers, consisting of defining the patient problem and iteratively refining the intervention. The clinical feasibility and
acceptability were examined via patient and intervention nurse interviews, which were audiotaped, transcribed, and deductively
content analyzed.
Results: The intervention comprised 2 synergistically operating elements: (1) daily medication reminders and routine assessment
of side effects with evidence-based self-care advice delivered in real time and (2) question prompt list (QPL) questions and
routinely collected individual patient adherence and side effect profile data used to shape nurses’ consultations, which employed
motivational interviewing to support adoption of self-management behaviors. A total of 4 consultations and daily alerts and advice
were delivered over 10 weeks. In total, 58% (10/17) of patients and 2 nurses participated in the pilot study. Patients reported
several benefits of the intervention: help in establishing medication routines, resolution of symptom uncertainty, increased
awareness of self-care, and informed decision making. Nurses also endorsed the intervention: it assisted in establishing pill-taking
routines and patients developing effective solutions to adherence challenges.
Conclusions: The REMIND system with nurse support was usable and acceptable to both patients and nurses. It has the potential
to improve adherence and side-effect management and should be further evaluated.
(JMIR Mhealth Uhealth 2017;5(12):e184)   doi:10.2196/mhealth.8349
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Introduction
Chronic myeloid leukemia (CML) is an uncommon clonal bone
marrow stem cell disorder. The disease has a triphasic natural
history—commencing in chronic phase, unless well controlled,
progressing to accelerated phase, and ultimately to blastic phase
with over 90% of patients being diagnosed in the chronic phase
[1]. Oral tyrosine kinase inhibitor (TKI) therapy is the standard
of care for patients with chronic-phase CML. Imatinib, nilotinib,
and dasatinib, currently first-line oral TKI therapies, are highly
successful in improving progression-free and overall survival
[2-4]. However, optimal adherence to TKIs is critical to
treatment success and survival, with continuous, daily dosing
required for an indefinite period, often lifelong [4,5], unless
complete deep molecular response has been achieved when a
treatment-free period can be tested [6,7].
TKIs are associated with numerous potential toxicities, including
myelosuppression, nausea, diarrhea, fatigue, and soft-tissue
edema, especially in the face and lower legs [8-11]. Given these
toxicities, it is not surprising that medication adherence is
problematic; a recent review found that one-third to one-quarter
of patients with CML have poor TKI adherence [12]. This is
serious as treatment response is compromised for patients with
less than 90% adherence [13,14]. Greater frequency of adverse
events and higher levels of patient-reported symptoms predict
lower levels of medication adherence [15,16]. Conversely, good
knowledge of disease and treatment and confidence in
medication self-management are linked to improved adherence
[15,17], whereas forgetfulness is the most common reason for
unintentional nonadherence [18]. These factors are potentially
modifiable by educational and behavioral interventions. There
is an urgent need to improve patient medication adherence
among patients with CML [4,19,20].
Mobile health (mHealth), defined as employing mobile devices
to support medical practice and public health, may improve TKI
adherence using cellular phone apps and text messages.
Internationally, phone text interventions have been tested to
prompt oral drug adherence in a number of chronic conditions,
including human immunodeficiency virus/acquired
immunodeficiency syndrome (HIV/AIDS) [21-27], diabetes
mellitus [28-31], asthma [32], and tuberculosis [33,34]. Studies
reported short- [21,23,24,28,29,32] and long-term [26,29]
improvements in adherence, with patients generally perceiving
text reminders as beneficial [21,22,27,33,34]. Reviews of phone
text reminder interventions have demonstrated efficacy in
enhancing patients’ compliance to drug therapy [35-39];
however, only one study of cancer patients was identified, which
was targeted at adolescents and young adults and phone text
messages were not utilized [40]. A secondary in-depth analysis
found no published trials that investigated a medication
adherence intervention that integrates nurse-led phone
consultations with mHealth systems in oncology [41].
Oncology nurses are central to providing education and coaching
in patient self-management of drug toxicities and medication
adherence [16,42,43]. Patient and clinician acceptability of
nurse-led mHealth interventions aimed at improving
postchemotherapy symptom management has been demonstrated
in solid tumors [44,45]. We conceived a multifaceted
intervention package consisting of 2 integrated elements
delivered over 10 weeks: (1) the REMIND mHealth system
comprising daily medication reminder texts and individualized
self-care advice based on self-reported side effects delivered in
real time and (2) nurse telephone consultations to promote
adherence to imatinib (Glivec) and coach patients in toxicity
self-management (Figure 1). Briefly, after the patient was trained
in using the REMIND system, he or she completed a Web-based
symptom survey and question prompt list (QPL), which was
used to guide the first nurse telephone consultation. Daily, the
patient was asked to respond to a text reminder message for
each dose based on his or her individual regimen.Once a week,
a text message was sent to patients to remind them to complete
an online symptom survey. For moderate to severe symptoms,
self-care information was sent to the patient in real time.
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Figure 1. Flowchart of the nurse-mediated telehealth (including REMIND system) intervention package (CML, chronic myeloid leukaemia; HP, health
professional; QPL, question prompt list; RA, research assistant; SMS, short message service).
Adherence and symptom profiles were available for clinician
review and used to guide 3 more nurse telephone consultation.
The aim of this paper is to describe the development of this
intervention and its clinical feasibility and acceptability. The
study is reported in accordance with the CONSORT eHealth
checklist (V1.6.1) [46].
Methods
Phase 1: Development of the Intervention
The framework for the development of effective, clinically
feasible, and sustainable interventions by Schofield and
Chambers was used to guide intervention development [47].
This intervention framework represents an expansion of the
Medical Research Council (MRC) framework for complex
interventions development [48]. The MRC framework provides
broad recommendations for intervention development, such as
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establishing the theoretical and evidence base and testing
procedures. The intervention development framework by
Schofield and Chambers specifies 7 features: (1) targeting cancer
type and stage, (2) tailoring to unique individual needs, (3)
promoting self-management, (4) efficient intervention delivery,
(5) ensuring evidence-based and theoretical grounding, (6)
specifying protocol training and adherence, and (7) confirming
stakeholder acceptability.
The features of the framework by Schofield and Chambers [47]
used to guide intervention development are described below.
Targeting
To understand the problem, a prior qualitative study by this
team with 16 patients with CML prescribed a TKI and 10 health
professionals was conducted to examine the nature, extent, and
reasons for medication nonadherence [49]. Findings revealed
that nonadherence was reported on at least one occasion among
75% of patients sampled with reasons for unintentional
nonadherence including forgetfulness or misunderstanding
medical instructions. Intentional nonadherence was related to
side effects and insufficient health care support. Health
professionals also experienced difficulty in accurately evaluating
the medication adherence of their patients. These findings, in
addition to those of others [17], indicate that intervention goals
should be to increase depth of knowledge of disease, treatment
regimen, and toxicities; increase confidence in self-management
of side effects; and prompt TKI self-administration according
to medical advice in relation to timing, dose, and frequency.
Tailoring
For the REMIND system, the timing of daily text-based
medication reminders could be set to suit individual preferences.
The evidence-based self-care advice was electronically delivered
in real time, corresponding to the individual’s responses to
weekly self-assessment of side effects. The structure and content
of the nurse consultations were directed by a QPL administered
electronically to the patient just before the first nurse
consultation.
Promoting Self-Management
Successful self-management requires the ability to self-assess
problems; marshal information, skills, or resources to
problem-solve; set goals; and implement the planned solution.
Key to this is self-efficacy, which is defined as a person’s beliefs
in his or her ability to succeed in a given task. Although the
REMIND system (medication reminders texts, side-effect
assessment, and self-care advice) facilitated self-assessment of
side effects and provided information and resources, coaching
in self-management and behavior change was accomplished by
the nurse-led phone consultations using motivational
interviewing, which is a client-centered method that allows
patients to explore and resolve their own ambivalence about
adopting a new behavior, such as medication adherence, and to
evoke self-motivation as opposed to traditional didactic health
advice provision [50].
Efficiency
The combined delivery methods of this intervention were used
to increase the efficiency of the intervention. Blending nurse
phone consultations with the REMIND system increased the
dose of the intervention, permitting the nurses to focus their
expertise on coaching. Exclusive use of communication
technologies for intervention delivery was intended to increase
access to those living in rural communities or those who were
too ill or had less time to attend face-to-face consultations.
Evidence and Theory
Both intervention content and delivery mechanism should be
based on theory and available evidence. The list of relevant drug
toxicities was generated using Monthly Index of Medical
Specialties and expert clinician advice (JFS). Authors (PS and
SA) updated their systematic review of self-care strategies for
chemotherapy side effects [51] with additional literature searches
to develop self-care recommendations for imatinib side effects
in conjunction with an expert clinician (JFS). A consumer with
CML (AD) iterative reviewed all content along with the
multidisciplinary study team. Motivational interviewing, the
central technique used the nurse delivery of content, arose from
self-determination theory [52], which is a framework of intrinsic
and extrinsic motives that facilitate or forestall behavior change.
Motivational interviewing by telephone is significantly
associated with improving medication adherence [53].
Protocolization
Interventions that layer digital technologies with targeted
clinician contact rely on adequate training and supervision to
ensure uniform delivery of content across intervention clinicians.
Standardized manuals were developed specifying (1) the
intervention content, including the resource manual describing
the disease, treatments, side effects, and evidence-based,
self-management advice; and (2) the training and supervision
protocols. Protocolization of standardized content and training
ensures a comprehensive knowledge base and attainment of
core skills required by the intervention nurses and consistent,
standardized, and reproducible delivery of the intervention
content.
Stakeholder Acceptability
Using a codesign process involving the end users (clinicians
and patients) throughout the development process optimizes
stakeholder acceptability [54,55]. Our stakeholder qualitative
research [49] directed the intervention goals and structure to
ensure relevance. A clinical nurse specialist was engaged to
write the nurse intervention manuals, detailing the content of
each intervention session. A resource manual to support the
provision of evidence-based advice was developed from
booklets, fact sheets, and websites which were sourced from
reputable peak cancer and other health bodies, in particular, the
Leukaemia Foundation of Australia. The intervention
development working party consisting of a consumer,
hematologists, hematology nurse specialists, clinical
psychologists, behavioral scientists, and an oncology pharmacist
reviewed iterative revisions of intervention and resource
manuals.
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Phase 2: Pilot Testing
Setting
This study was conducted in a comprehensive cancer hospital
in Melbourne, Australia.
Design
A qualitative research design was used to examine the clinical
feasibility and acceptability of the intervention package to
patients and nurses.
Participants
Participants were patients who received the intervention and
nurses who delivered the intervention. Inclusion criteria for
patients were as follows: age >18 years, proficiency in English,
a confirmed diagnosis of chronic-phase CML with no signs of
progression, and >3 months of continuous treatment with
imatinib (Glivec) with no evidence of drug resistance. On the
basis of feedback from the first 3 patients in this pilot testing
phase, this last criterion was changed to treatment with imatinib
and no evidence of drug resistance. Exclusion criteria were
cognitive or psychological difficulties as assessed by the
patient’s treatment team and being too unwell. In total, 2 clinical
nurse consultants with postgraduate qualifications in cancer
nursing and extensive experience in hematological oncology
were trained to deliver the intervention.
Nurse Training
The nurses were trained to deliver the structured telephone
consultations and use the REMIND system in a 1-day workshop,
facilitated by a clinical communication expert (PS). The
workshop comprised an overview of the project and intervention
manual and training in (1) identifying and responding to
emotional cues on the phone, (2) exploring concerns about
medication adherence and providing evidence-based self-care
advice, and (3) coaching patients using motivational
interviewing techniques. Didactic instruction was complemented
by 2 role-play sessions with a simulated patient and facilitator
feedback: 1 in the workshop and 1 in a subsequent phone
consultation, which was audiorecorded for self-appraisal and
facilitator feedback.
Procedure
Potentially eligible participants were identified by clinician
referral or pharmacy records of imatinib dispensing and
examined for eligibility as per the eligibility criteria by the
research assistant. After confirming eligibility and suitability
with the treating clinician, patients were approached either
face-to-face at outpatient clinic visits or over the telephone. An
appointment was made with interested participants to review
and sign the consent form, complete a baseline questionnaire,
and be trained to use the REMIND system. All patients then
received the intervention over 10 weeks and at the end of the
intervention, completed a follow-up questionnaire. The
patient-reported outcomes in both questionnaires covered quality
of life [56], psychological morbidity [57], and self-management
[58].
Patient and Intervention Nurse Interviews
Following completion of the intervention, consenting patients
and intervention nurses participated in a semi-structured
telephone interview of 20 to 40 min. Separate interview
schedules were developed for patients and health professionals.
Both interview schedules covered perceptions of the intervention
package, including content, timing, and perceived utility of each
component of the REMIND system and the nurse consultations,
perceived impact of the intervention on adherence and
self-management, overall satisfaction with intervention, and
recommended changes. All interviews were audiorecorded and
transcribed verbatim.
A content analysis was undertaken to identify themes [59]; 2
investigators (APS and JW) analyzed intervention patient data
and 2 investigators (PS and JW) analyzed nurse data separately.
The process involved iterative movement between transcripts,
rereading to establish familiarity with content and reflection of
ideas. Similar content was collated and summarized to form
themes with codes assigned by each analyst. Following analysis
completion, all data analysts met to discuss results of their
respective data. Disagreements between coders were identified
and discussed until agreement was reached. Coding themes
were then agreed upon, and the data from each group were coded
into these themes. Themes were then collapsed or divided
through consultation and discussion. As the interviews covered
similar topics, perspectives of the 2 groups were aggregated.
Survey outcomes were not analyzed due to sample size.
Results
Phase 1: Development of the Intervention
The REMIND System
The REMIND system was a hosted Web application, deployed
on the Amazon Web Services cloud platform as an EC2 instance,
with multiple Web- and text-based interfaces provided for a
variety of users and a range of services that control text
messages sent to a third-party short message service (SMS) text
messaging Gateway (Figure 2). It comprises the following:
1. A database of all user information, including patient and
health professionals’ log-in information; patient phone
numbers and preferred notification time for medication
reminders; and a log of all responses to daily reminders and
answers to weekly survey questions
2. A Web-based application that allows patients and health
professionals to view, and for health professionals to edit
information regarding users, and patients to edit responses
to reminders and symptom survey answers. The pages
displayed by this application are designed for both
laptop/desktop and mobile phone screens.
3. An automatic nightly service that pulls responses from the
SMS Gateway, updates the database, creates SMS messages
for the next day from information in the user database, and
then forwards these messages to the SMS Gateway to be
queued to be sent out at the preferred notification times.
This program is sensitive to time zone and daylight saving
and automatically adjusts the send-time of messages
according to the local time of the patient’s location.
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Figure 2. REMIND system representation. (A) Architecture of the REMIND system showing context of interaction with different types of users
(patients, health care professionals, and administrators) and external SMS Gateway service. The patient receives reminders on his or her cellular phone,
sent from the SMS Gateway, and can interact with the weekly symptoms survey via a browser on a standard computer or a smartphone. (B) Screenshot
of patient dashboard, showing graphs (from left to right) of scores (for severity and irritation) for symptom (in this case, nausea) over time, bar chart
indicating daily adherence (measured by response), and pie chart showing overall adherence rate. (C) Screenshot of specific symptoms—severity graph
for nausea—as displayed on the cellular smartphone interface.
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Daily or twice-daily cellular phone reminder message were sent
via the REMIND system to each patient for each dose based on
patients’ individual dosing regimen. Patients were asked to reply
with a Yes message once the dose was taken or No if not taken.
Adherence, patient compliance with imatinib, was considered
to be a response of Yes received via a phone message from
patients. If no reply was received within a designated time period
(2 hours), this was interpreted as No.
Once a week, patients completed a side-effect assessment online
via the REMIND system using a smart cellular phone or
computer. For each of 11 potential side effects/symptoms
patients may experience when taking imatinib, they reported
severity and extent of bother on a scale of 1-10 for each side
effect present. Automatically generated self-care advice was
customized to the symptoms reported and sent to the patients
in real time.
If 10% of scheduled doses in a week were missed or if
side-effect severity was ≥4, this was included on a daily digest,
which was forwarded to the nurse assigned to that patient via
email. The nurse could decide to contact the patient outside of
the scheduled consultations to discuss self-management
strategies or address medication adherence barrier(s).
Phone-Based Nurse Consultation Sessions (4 Sessions
in Weeks 1, 2, 6, and 10)
In the week before the first nurse consultation, the patient
reported medication adherence daily, completed the weekly
medication side-effect assessment, and selected questions from
the CML-specific QPL. QPLs are structured list of commonly
asked questions customized to disease type and have been found
to improve clinician-patient communication and increase the
amount of desired information received by patients [60]. The
nurse accessed the REMIND system to view the patient’s
responses to shape content of the first nurse consultation session.
It covered the following: (1) building rapport; (2) addressing
questions noted on the QPL; (3) establishing common ground
by assessing patients’ understanding of their diagnosis, current
symptom experience, and medication regimen; (4) discussing
the patient’s medication adherence and explored adherence
barriers; (5) coaching to address barriers; (6) discussing
medication side effects; (7) coaching in evidence-based self-care
strategies targeting each reported side effect; and (8)
summarizing the consultation and assessing patient
understanding. The subsequent consultations used the REMIND
system’s patient-reported information to cover (4) to (8).
Phase 2: Pilot Testing
A total of 10 out of 17 patients agreed to participate, with a
response rate of 58% (Figure 3). Of the participants, 9 completed
all components of the intervention and 1 participant ceased
before week 10 due to travel. Another participant was lost to
follow-up. In total, 9 patients and 2 nurses completed interviews.
Participant demographics are described in Table 1. Median age
of patient participants was 54 years, ranging from 35 to 72 years;
the majority of participants, that is, 6 out of 9, were male (67%).
The 9 patients who participated in the pilot testing had received
imatinib therapy for a median of 4 years before the start of the
study, with a range from 15 days to 12 years.
Figure 3. CONSORT flowchart of participants completing each intervention component and data collection point (RA refers to research assistant).
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Table 1. Participant demographics.
Patients (N=9)Characteristics
Age (years)
54 (44.5-60.0)Median (interquartile range)
35-72Range
Sex, n (%)
6 (67)Male
3 (33)Female
Country of birth, n (%)
7 (78)Australia
1 (11)China
1 (11)England
English as first language, n (%)
8 (89)Yes
1 (11)No
Education (highest level completed), n (%)
3 (33)Secondary/high school
1 (11)Trade/Technical and Further Education
3 (33)Bachelor’s degree
2 (22)Postgrad diploma/masters/PhD
Time since diagnosis
4 (1-13)Median (interquartile range in years)
1 month-17 yearsRange
Imatinib treatment duration a
48 (16-123)Median (interquartile range in months)
15 days-12 yearsRange
Employment status, n (%)
4 (44)Full time
2 (22)Part time
1 (11)Home duties
2 (22)Retired
Residence
4 (44)Metropolitan
5 (56)Rural
aDuration on imatinib at the start of REMIND study: Patient 2 (9 years), Patient 3 (5 years), Patient 4 (4 years), Patient 5 (2.5 years), Patient 6 (11.5
years), Patient 7 (1 year), Patient 8 (1.6 years), Patient 9 (12 years), Patient 10 (2 weeks).
The system administrator as detected by the REMIND system
monitored adherence (Table 2). The SMSs were sent on time
(<1 hour) to patients on 671 out of 684 (98.0%) occasions, with
a range of 0-7% participants experiencing SMS failure and a
range of 0-22% participants not replying to SMS messages at
all, over the total study period. In total, 2 patients reported that
up to 40% of messages were not received by them by the
appointed time due to problems with slow networks, particularly
in rural areas.
A number of common themes were identified across the nurses
and patients.
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Table 2. System administrator details of SMS (short message service) texts sent and answered by patients.
Patient failure to answer SMS when sent, n (%)SMS failure, n (%)Total daysPatient
Not at allIn 2 hours of SMS
5 (7)5 (7)5 (7)742
3 (4)3 (4)1 (1)793
3 (5)4 (7)0 (0)624
10 (15)14 (20)0 (0)695
6 (5)8 (7)0 (0)1206
4 (5)4 (5)0 (0)797
17 (22)32 (41)1 (1)808
0 (0)2 (4)0 (0)579
8 (11)8 (11)4 (5)7510
Accountability and Routine
Patients and nurses reported that they found the intervention
acceptable and helpful for improving adherence through
enabling patient accountability. A newly diagnosed patient
stated:
...it definitely helped reinforce habit when I was at
the start of getting on, getting this medication into
routine. [PT10]
Longer-term patients with changed circumstances also benefited:
I’ve had overseas visitors for the last 2 weeks so I’m
out of my usual routine…I’m sure I would have missed
some of my drug taking…had I not had the reminders.
[PT6]
A nurse spoke about the intervention for modifying adherence
behavior:
...we discussed the barriers that she had to taking her
tablet regularly. And then over time she softened and
realized that she could develop strategies to overcome
the problems... [N2]
Alleviating Psychological and Symptom Distress
Patients spoke about the benefits for alleviating psychological
and symptom distress. The intervention was reported to be
particularly useful for easing uncertainty about symptoms/side
effects. One of the participants said:
It was good...if someone (nurse) noticed a change in
symptoms I might not have picked up on it, and they
were able to discuss it with me and find out why it
might have happened. [PT3]
Patients felt reassured by the intervention:
...the good part...was the personal touch...it’s just that
really nice reminder that there’s someone out there
that’s half looking out for you. [PT5]
Access to expert advice was also valued.
You do talk about things with your partner but you
don’t go down some of the tracks that you probably
would with a nurse...they prompt information out of
you from their knowledge. [PT5]
Supporting Self-Efficacy
The intervention was identified as useful for uptake of
self-management strategies and encouraging informed decision
making. One patient commented:
Because I’ve been doing this, it makes me think about
other things like diet. [PT2]
Another patient explained self-care options and informed choice:
...we did discuss that I could take Imodium (diarrhoea
medication) or something like that if I wanted to but...I
didn’t want to take any more tablets...where I can’t
get to a toilet and if I did need, like a wedding, I’d
take Imodium to make sure that I didn’t have any
accidents. [PT3]
Functionality of Intervention
Overall, patients found the REMIND system highly usable.
Although a patient (PT6) described the process as “pretty
straightforward,” another mentioned:
I suppose the only bit I found a bit off-putting the most
was the questions around depression and anxiety.
[PT10]
Patients routinely had access to a cellular phone; however, one
patient admitted that they:
...struggled with that [the 2 hour window to respond].
[PT 7]
Most patients found the system reliable and received the
messages at the appointed time, but there were exceptions:
There were maybe three times that the computer
system either didn’t send a text or it was an hour or
2 late... [PT3]
A rural patient had ongoing problems as he had an unreliable
telephone network, and reported as many as 40% of the text
messages delayed by 30-45 min [PT10]. The 2 participating
nurses differed in their opinion about the REMIND system: one
found it easy but the other needed time to become familiar with
it. Both nurses found the initial QPL useful, comprehensive,
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and helpful in shaping the consultation content and facilitating
rapport. The resource and intervention manuals supplied to the
nurses were endorsed as comprehensive and very helpful,
particularly the session checklist. Reorganization of the manual
was suggested:
...I find these manuals just a bit fiddly to work around
so that’s why I’ve got like post it notes
everywhere...it’d be good if there was tabs or
something... [N1]
Training in motivational interviewing was perceived as
beneficial:
I gained skills in the motivational interviewing
techniques which I continue to use. [N2]
Both nurses felt that the timing and number of interview sessions
were appropriate with no recommendations for alterations. Both
suggested that daily digest (or summary) of patient adherence
and symptom responses should be emailed less frequently than
daily because it was “too much.”
Overall, 3 patients fell below 90% reported adherence levels.
The protocol stated patients with adherence below 90% should
have been contacted outside to the scheduled calls. However,
both nurses expressed that they were in a quandary when patients
did not SMS Yes, but relied on their experience and decided not
to make extra contact. One of the nurses commented:
My personal experiences on the phone calls has been
that patients report that they are adhering to their
medications even if they’re not responding to their
SMS, so it’s kind of a bit tricky...I guess it’s a guide
as to whether they’re taking their tablet but it’s not
definitive... [N1]
Optimal Intervention Target Group
In terms of timing, most patients thought the intervention would
be most beneficial at the start of therapy or, even at diagnosis:
...if they’re just starting out on Glivec I reckon it
would be invaluable. [PT2]
The newly diagnosed participant (PT10) commented that it was
“good timing” for him. Nurses agreed suggesting:
...A lot of people said it would have been helpful when
they were first diagnosed. [N1]
However, they also suggested that the intervention has broad
applicability:
Not only in patients with CML but...there’s a whole
lot of new oral medications on the market now for a
whole variety of cancers and conditions. [N1]
Discussion
Principal Findings: Intervention Development
The framework by Schofield and Chambers was successfully
applied to the development process. Preliminary qualitative
research [49] served to delineate the patient problem and aligned
the intervention goals with patients’ needs. Relevant evidence
and theoretical perspectives were investigated through literature
reviews and combined with reputable patient education material
to create appropriate evidence-based content and resources for
the intervention. The automated features of the REMIND system
permitted flexibility in intervention content and responsiveness
to individualized concerns. Combining automated reminders,
side-effect assessments, and self-care advice with personalized
coaching fostered self-management. The dose of the intervention
was maximized by using resource-intensive nursing expertise
efficiently by basing the content of consultations on automated
reminders and symptom assessments. While the standardized
material supports reproducibility, the codesign processes
promote acceptability. These approaches are consistent with the
current literature that recognizes improved knowledge of disease
course, medication, and management of side effects paired with
expert clinician support as integral to improving medication
adherence in patients with CML [15].
Principal Findings: Acceptability and Clinical
Feasibility of Intervention
Pilot testing demonstrated that this intervention was able to be
implemented and integrated into the clinical management of 10
patients with CML. It was highly acceptable to both patients
and nurses. Most patients indicated that receiving and
responding to the text reminders prompted medication adherence
due to accountability. Nurses felt many long-term patients
already had well-established routines. Although most patients
agreed, those who changed their routine, for example, dining
out, found the text reminder was useful to them. Nevertheless,
both patients and nurses believed that this intervention would
be most useful for patients at commencement of drug therapy.
Patients found discussing their medication side effects with the
nurse and receiving expert advice regarding self-management
highly beneficial. Other benefits included increasing awareness
of self-care, encouraging informed decision making and feeling
reassured.
The usability of the intervention was high: most patients
expressed ease with text reminders and the weekly symptoms
survey. A small proportion of patients did experience difficulty
either receiving or responding to the text within 2 hours either
because they were not used to carrying a cellular phone or slow
Internet speed. However, as the adoption of cellular
phones/devices continues to rise and Internet speed and
geographic coverage improve [61], this barrier is likely to
diminish in future.
The nurses endorsed all facets of the system, including the
administration website, QPL, resource and intervention manuals,
session checklists, symptom surveys, automatically generated
advice, and nurse phone consultations. They suggested
improving the layout of the intervention manual and less
frequently emailed daily digest (or summary) of patient
adherence and symptom responses. One departure from the
intervention protocol was nurses not calling patients when
patients were less than 90% adherent. It is recommended that
the application of the protocol is routinely monitored and
departures are addressed through ongoing supervision and
training. In particular, the importance of contacting patients
who are less than 90% adherent immediately, not waiting until
the next scheduled consultation, should be emphasized.
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Supervision could include role playing these scenarios to
increase the skills to deal with issue.
Limitations
The limitations of this study include a relatively small sample
of nurses and patients used to pilot test this intervention. Given
the sample size, it is unlikely that saturation was reached. As
CML is a relatively rare disease, it proved difficult and
time-consuming to achieve this modest sample size.
Furthermore, most patients had been diagnosed years before
the study, hence possibly had higher levels of medication
adherence than those newly diagnosed. Future trials may need
to explore a different cancer type to test the impact of this
intervention upon oral medication adherence. As high-cost oral
therapeutics in oncology continue to become more prevalent,
it will be critical to ensure that adherence is high to deliver the
anticipated survival outcomes to ensure that the health care
expenditure is justified [4].
Comparison With Prior Work
Despite phone text reminder interventions for patients’ with
HIV [37], cardiac disease [35], and other chronic conditions
[38] demonstrating improvements to medication adherence, not
all studies included nurse or counselor supportive care in the
intervention. In our study, an innovative medication intervention
was developed and tested, which combined 2 features: (1) daily
medication reminders and routine assessment of side effects
with evidence-based self-care advice delivered in real time; and
(2) QPL questions and routinely collected individual patient
adherence and side-effect profile data used to shape nurses’
consultations, which employed motivational interviewing to
support adoption of self-management behaviors.
A secondary analysis [41] identified 2 randomized controlled
trials of phone text reminder adherence interventions combined
with counseling sessions, 1 study in patients with HIV [62,63]
and the other in patients with diabetes, which has since been
retracted. Qualitative findings indicated beneficial experiences
where patients with HIV emphasized emotional and mental
support from health care providers in addition to medical care
[63]. A similar finding has been described in patients with
tuberculosis who reported feeling cared for and thankful that
health professionals were available to answer their questions
while reminders instilled a sense of responsibility and personal
accountability for their treatment [33]. Comparably, patients
receiving phone symptom monitoring and nurse support while
undergoing chemotherapy for cancer have reported feeling
reassured [45]. Although previous studies have recognized text
reminders prompt adherence in the home environment as well
as on vacation [21,34], some patients believed reminders may
be more useful earlier in diagnosis before habits being formed
[34]. Many of these sentiments were also expressed by patients
in our study.
Patients in our study reported technological difficulties and an
absence of cellular phones, whereas additional reasons for not
responding have been reported in the literature. These include
problems with cellular phones, out-of-phone credit, the phone
being switched off, the phone’s battery running out, and losing
the cellular phone [25,33,63]. It will be difficult for health
services to overcome these types of practical problems and they
may have to be accepted as a limitation of this type of
intervention.
Conclusions
This paper contributes to the evolving knowledge base of how
to develop an evidence-based, acceptable, and potentially
effective complex intervention. We have provided examples of
strategies that may assist researchers and clinicians in developing
or trying out a new psychoeducational intervention. These
strategies can enhance intervention methodological rigor for
testing in a randomized controlled trial through standardized
intervention content and training; and implementation
considerations such as improved clinical acceptability through
the codesign process. To our knowledge, this is the first cancer
medication adherence intervention that integrates a mHealth
platform with tailored phone consultations based on
patient-provided questions, adherence rates, and side-effect
profiles provided by nurses trained in motivational interviewing.
The intervention was clinically feasible. Patients and nurses
endorsed this intervention as acceptable and useful particularly
for a newly diagnosed patient. The next step will be to conduct
an appropriately powered randomized controlled trial targeting
a wider range of cancer diagnoses that are currently managed
by oral therapeutics to ensure adequate recruitment and assess
broader applicability. This future research will focus on patients
at diagnosis and assess adherence with an electronic pill
monitoring device to examine short- and long-term adherence.
In addition, because chronic illnesses are more prevalent among
older citizens, many people will have 2 or more comorbidities
requiring self-management with oral medications. Future
iterations of the REMIND platform should cater for multiple
medications for multiple comorbidities. Health care resource
utilization and sustainability of the intervention should also be
considered by integrating an economic evaluation into the
randomized controlled trial.
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